SAVA Share Price Performance
US$4.19
-20.67 (-83.15%)
Price US$4.19
Share PriceUS$4.19
Cassava Sciences, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
SAVA Community Narratives
There are no narratives available yet.
Recent SAVA News & Updates
Cassava Sciences, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.55
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Cassava Sciences, Inc. Competitors
Snowflake Analysis
About SAVA
- Founded
- 1998
- Employees
- 30
- CEO
- WebsiteView website
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: 0.3%
- 3 Months: 8.5%
- 1 Year: 17.3%
- Year to Date: 15.0%
In the last week, the market has been flat. Meanwhile, the market is actually up 17% over the past year. Earnings are forecast to grow by 15% annually. Market details ›